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Abstract. The paper presents data from a study of the neuroendocrine
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acalculous cholecystitis. Adrenergic and cholinergic activities as well
as cortisol secretion have significantly changed.
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Introduction
Bronchial asthma (BA) is a global problem in the
internal medicine, leading among respiratory diseases;
therefore it remains an actual problem for a scientific
research both in Ukraine and around the world [1, 6,
7]. Unfavorable epidemiologic situation, severe,
uncontrolled course of BA are caused by lack of
timely detection of sick people when the signs are not
significant, by such factors as allergens, xenobiotics,
chronic nidi of viral and bacterial infection, parasitic
invasions, use of enzymatic domestic chemicals,
uncontrolled use of a great variety of drugs, active and
passive cigarette smoking as well as stresses [6, 8].
According to data of different authors, a combined
course of BA and diseases of digestive organs occurs
in 8-50% of cases, and gastrointestinal diseases
occur combined with atopic BA twice as often as
with infection-dependant BA [3].
Different authors describe the development of
gastric ulcer, gastric and duodenal erosions, chronic
gastritis, duodenitis, reflux esophagitis and sliding
hiatal hernia, duodenogastric reflux, changes in the
liver, inflammation of the biliary tract and pancreas in
the patients with chronic inflammatory diseases of the
lungs and bronchi [2, 4]. Chronic acalculous cholecystitis
(CAC) combined with BA, according to some authors, is
known for the prevalence of aseptic inflammation in the
gallbladder (GB), interrelation of exacerbations with BA
exacerbation, more torpid, compared to BA, and atypical
course with less intensive pain syndrome, prevalence of
dyskinetic phenomena over the inflammatory ones with
formation of hypokinetic dyskinesias of the GB [3, 4].
With hypokinetic dyskinesias of the GB and a basis
therapy of BA, amplification of CAC is predominant [5].
Using basic therapy and â-adrenoceptor agonists as well
as cholinergic antagonists contribute to GB hypokinetic
dyskinesias intensification [4, 9].
Objective
To study the features of adrenergic and cholinergic
regulations of bronchial tone and that of the gall-
bladder in patients with combined course of chronic
acalculous cholecystitis and bronchial asthma.
Material and methods
92 patients were involved in the study: 30 patients
with mild and moderate persisting BA (1st group), 30
patients with mild and moderate persisting BA of
comorbid CAC in the acute phase (2nd group), 32
patients with CAC in the acute phase (3rd group) and
a control group - 30 practically healthy individuals
(PHI) of the respective age.
Ventilation lung function was studied by means of
a computer Spirograph «Pneumoscope» company
«Jaeger» (Germany), «Spirosift 3000» company
«Fukuda Denshi» (Japan). The degree of disturbance
in the respiratory function was evaluated through an
analysis of spirography findings and a curve «flow-
volume» by comparing the findings obtained with the
appropriate parameters for a given age, sex, height
and weight before and after pharmacological tests
with salbutamol. The range of normative parameters
was considered 80-120% of appropriate. Ultrasono-
graphic testing of the liver, the GB, and the pancreas
was carried out in 100% of patients by means of an
ultrasound scanner «Au-4 Idea» (Biomedica, Italy).
The catecholamine depositing function of erythro-
cytes (CDE) was studied according to the H.I.
Mardar’s and D.P. Kladienko’s method. The
cholinergic system tone was assessed by the activity
of acetylcholinesterase (AChE) in the blood serum.
Results and discussion
All the patients with BA and BA combined with
CAC had a marked predominance of the
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parasympathetic nervous system, as evidenced by the
established significant decrease of CDE (Table 1) in
patients with isolated asthma is 1.4 times (p <0.05), in
patients with asthma combined with CAC - there was
more intense inhibition of enzyme activity – in 1.8
times (p <0.05) and in patients with CAC of the 3rd
group there were identical changes – a decreased
activity of CDE in 1.6 times (p <0.05) with significant
intergroup differences between the groups (p <0.05).
These data suggest, that patients, suffering from
asthma combined with CAC, have a cholinergic
imbalance due to, vagotonia, established on clinical
grounds, and also due to AChE activity inhibition. This
vegetative background promotes BA development,
mucus hypersecretion by the bronchial glands, dyscrinia
as was found in the patients under examination. It also
leads to a lack of the GB contractility, development of
sphincter of Oddi hypertension dysfunction, and CAC.
The distribution of patients according to the severity of
asthma and correlation analysis showed a direct
interdependence between the severity of asthma (by
FEV1 index-forced expiratory volume) of AChE
activity (r = 0.784, p <0.05).
An analysis of the studies showed significant
changes in the CDE of the surveyed individuals. For
instance, the CDA in the individuals of groups 1 and
2 was lower by 1.6 and 2.4 times respectively (p
<0.001) than in the group of PHI; in the patients of
the 3rd group – the changes were minor – a decline
of 14.6% (p<0.05) compared with practically healthy
individuals (Table 1). It should be noted, that the
CDE in the first group was 64. 9% lower than in the
second one. The patients of the first group had a
particular catecholamine (CA) depositing intensity
depending on the presence of the concomitant CAC.
For instance, the patients with an isolated BA had a
significantly lower CA (by 1.5 times) per one
erythrocyte (ð<0.05). The patients, suffering from
BA combined with CAC, had by 3 times less CA per
one erythrocyte (ð<0.05) than normal indices, and
that was by1.5 times less than in the first group
patients (ð<0.05). The above mentioned changes
occur in the patients of the 3d group too. The number
of CA in an ordinary erythrocyte becomes a little less
(for 13%) (ð<0.05). Participation of sympatho-
adrenal system in the pathogenesis of asthma
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occurrence has been proved, however, in patients
with asthma and CAC, the ability to deposit CA,
when combined with CAC has significantly dropped.
The study of cortisol density in the blood serum
of the patients under examination showed its
significant drop in all groups observed (table 1). For
instance, the first group patients’ blood contained 2.7
times (ð<0,05) less cortisol than that of PHI; in the
patients of the second group the inhibition of the
functional state of the adrenal cortex was even more
intense – cortisol was lower than its index in the
control group by 3.7 times (ð<0,05); the 3d group
patients had the maximum drop in cortisol secretion
by 1.7 times (ð<0,05) with reliable intergroup
difference (Table 1). Thus, one of the risk factors for
BA development is a significant inhibition of cortisol-
synthetic adrenocortical function. This is, probably,
one of the pathogenic mechanisms of BA, and, in
particular, the progression of bronchial inflammation
and formation of â-adrenergic mediators, insensible to
the influence of sympathoadrenal system, and of
facilitating adrenergic imbalance. The results of the
study of cortisol amount in patients, suffering from
BA combined with CAC depending on the BA
severity rate, prove this hypothesis.
In particular, the patients with BA of ²² degree had
lower cortisol concentration in their blood than those
of the PHI group by 2.3 times (ð<0,05), the same
index in the patients with BA of ²²² degree was lower
by 2.8 times(ð<0,05), besides, in the patients with
BA of ²² degree there was a reliably maximum
decrease of cortisol and of synthetic adrenocortical
function – by 3.7 times (p <0.05) with the presence
of reliable intergroup differences (p <0.05). The
correlation analysis indicates a significant direct
relationship between the FEV1 index and cortisol
levels in patients with BA combined with CAC (r =
-0,725, p <0,05). Thus, the patients under the study
experienced a significant inhibition of synthesis and
decrease in blood cortisol, which correlates with the
severity of asthma and is a risk factor for progression
of an inflammation in the GB. Table 2 shows a
matrix of correlations between indices of CDE,
AChE activity, cortisol levels and indices of lung
function, morphological and functional properties of
erythrocytes in patients with asthma and CAC.
According to statistical data, there is a tight direct
correlation between FEV1indices and the cortisol
amount in the blood, AChE and CDE activity, that is,
adrenal insufficiency(cortisol deficiency in the blood),
reduced AChE activity, intensifying vagotonia, as well
as an increasing resistance to CA (reduced CDE) all
contribute to BA and CDE development. CDE indices
are, to a considerable degree, interdependent with the
contractibility of the GB, of choleresis effort (CE)
and lithogenic index (LI). A reciprocal proportion
between AChE activity indices and a duration of
sphincter of Oddi spasm during the second phase of
choleresis , as well as the direct interdependence
between the AChE and LI activities which proves,
that it is vagotonia which causes all above mentioned
disorders. A negative correlation between the index
of cortisol in the blood and sialic acid content
indicates a direct pathogenetic basis of inflammatory
changes in the GB and the bronchi.
Conclusion
The base of regulatory neuroendocrine and
paracrine mecganisms imbalance, contributing to a
development of bronchial asthma, is the cholinergic
imbalance (reduction in blood acetylcholinesterase
activity, hypertensive sphincter of Oddi dysfunction),
adrenergic imbalance (reduction of reversibility of
bronchospasm with inhaled β-agonists under
conditions of comorbidity (12-13% vs. 16-23% for
isolated asthma)), reduction in catecholamine-
depositing erythrocytes function, hypokinetic
gallbladder dysfunction, adrenal dysfunction
(decreased cortisol levels) that contribute to the
development and progression of chronic cholecystitis
against a background of hypokinetic gallbladder
dysfunction.
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